Glycated proteome: From reaction to intervention

Proteomics - Clinical Applications

Volumn 7, Issue 1-2, 2013, Pages 155-170

  Kulkarni, Mahesh J ^a   Korwar, Arvind M ^a   Mary, Sheon ^a   Bhonsle, Hemangi S ^a   Giri, Ashok P ^a  

^a NATIONAL CHEMICAL LABORATORY   (India)

Author keywords

Aging; Diabetes; Glycation; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; ALDEHYDE REDUCTASE; AMYLOID BETA PROTEIN; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN; ARYLDIALKYLPHOSPHATASE 1; BISPHOSPHOGLYCERATE MUTASE; CALMODULIN; CATALASE; CD59 ANTIGEN; CHEMICAL COMPOUND; COPPER ZINC SUPEROXIDE DISMUTASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOLASE; FIBRINOGEN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE (NADP)(PHOSPHORYLATING); HEMOGLOBIN; IMMUNOGLOBULIN; LOW DENSITY LIPOPROTEIN; N PHENACYL DIMETHYLTHIAZOLINIUM CHLORIDE; N PHENACYL THIAZOLINIUM BROMIDE; NITRIC OXIDE SYNTHASE; SCHIFF BASE; TRANSFERRIN; UNCLASSIFIED DRUG;

AGING; ATHEROSCLEROSIS; DEGENERATIVE DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCATION; HUMAN; HYPERLIPIDEMIA; IN VIVO STUDY; ISCHEMIC HEART DISEASE; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; MOLECULAR MECHANICS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; PROTEOME; PROTEOMICS;

EID: 84872717719     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201200101     Document Type: Review

References (183)

1. Maillard, L. C., The action of amino acids on sugar; the formation of melanoidin by a methodic route. Comptes Rendus Hebdomadaires Des Seances De L Academie Des Sciences 1912, 154, 66-68.
2. Thornalley, P. J., Langborg, A., Minhas, H. S., Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J. 1999, 344, 109-116.
3. Faist, V., Erbersdobler, H. F., Metabolic transit and in vivo effects of melanoidins and precursor compounds deriving from the Maillard reaction. Ann. Nutr. Metab. 2001, 45, 1-12.
4. Ames, J. M., Determination of N-epsilon-(carboxymethyl) lysine in foods and related systems. Ann. NY Acad. Sci. 2008, 1126, 20-24.
5. Cai, W., Ramdas, M., Zhu, L., Chen, X. et al., Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc. Natl. Acad. Sci. USA 2012, 109, 15888-15893.
6. Brownlee, M., Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414, 813-820.
7. Lapolla, A., Fedele, D., Traldi, P., The role of mass spectrometry in the study of non-enzymatic protein glycation in diabetes. Mass Spectrom. Rev. 2000, 19, 279-304.
8. Lapolla, A., Fedele, D., Seraglia, R., Traldi, P., The role of mass spectrometry in the study of non-enzymatic protein glycation in diabetes: an update. Mass Spectrom. Rev. 2006, 25, 775-797.
9. Capote, F. P., Sanchez, J. C., Strategies for proteomic analysis of non-enzymatically glycated proteins. Mass Spectrom. Rev. 2009, 28, 135-146.
10. Zhang, Q. B., Ames, J. M., Smith, R. D., Baynes, J. W. et al., A perspective on the maillard reaction and the analysis of protein glycation by mass spectrometry: Probing the pathogenesis of chronic disease. J. Proteome Res. 2009, 8, 754-769.
11. Morais, M. P., Mackay, J. D., Bhamra, S. K., Buchanan, J. G. et al., Analysis of protein glycation using phenylboronate acrylamide gel electrophoresis. Proteomics 2010, 10, 48-58.
12. Zhang, Q. B., Tang, N., Schepmoes, A. A., Phillips, L. S. et al., Proteomic profiling of nonenzymatically glycated proteins in human plasma and erythrocyte membranes. J. Proteome Res. 2008, 7, 2025-2032.
13. Gadgil, H. S., Bondarenko, P. V., Pipes, G., Rehder, D. et al., The LC/MS analysis of glycation of IgG molecules in sucrose containing formulations. J. Pharm. Sci. 2007, 96, 2607-2621.
14. Priego-Capote, F., Scherl, A., Muller, M., Waridel, P. et al., Glycation isotopic labeling with C-13-reducing sugars for quantitative analysis of glycated proteins in human plasma. Mol. Cell. Proteomics 2010, 9, 579-592.
15. 6-reducing sugars. Methods Mol. Biol. 2011, 728, 219-232.
16. Mittelmaier, S., Pischetsrieder, M., Multistep ultrahigh performance liquid chromatography/tandem mass spectrometry analysis for untargeted quantification of glycating activity and identification of most relevant glycation products. Anal. Chem. 2011, 83, 9660-9668.
17. Bhonsle, H. S., Korwar, A. M., Kote, S. S., Golegaonkar, S. B. et al., Low plasma albumin levels are associated with increased plasma protein glycation and HbA1c in diabetes. J. Proteome Res. 2012, 11, 1391-1396.
18. Meerwaldt, R., Links, T., Graaff, R., Thorpe, S. R. et al., Simple noninvasive measurement of skin autofluorescence. Ann. NY Acad. Sci. 2005, 1043, 290-298.
19. Mulder, D. J., Water, T. V., Lutgers, H. L., Graaff, R. et al., Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. Diabetes Technol. Ther. 2006, 8, 523-535.
20. Lutgers, H. L., Graaff, R., Links, T. P., Ubink-Veltmaat, L. J. et al., Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006, 29, 2654-2659.
21. Meerwaldt, R., Lutgers, H. L., Links, T. P., Graaff, R. et al., Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007, 30, 107-112.
22. Dorrian, C. A., Cathcart, S., Clausen, J., Shapiro, D. et al., Factors in human serum interfere with the measurement of advanced glycation endproducts. Cell Mol. Biol. (Noisy-le-grand) 1998, 44, 1069-1079.
23. Lyons, T. J., Basu, A., Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers. Transl. Res. 2012, 159, 303-312.
24. Rondeau, P., Bourdon, E., The glycation of albumin: structural and functional impacts. Biochimie 2011, 93, 645-658.
25. Arif, B., Ashraf, J. M., Moinuddin, Ahmad, J. et al., Structural and immunological characterization of Amadori-rich human serum albumin: role in diabetes mellitus. Arch. Biochem. Biophys. 2012, 522, 17-25.
26. Ahmad, S., Moinuddin, Ali, A., Immunological studies on glycated human IgG. Life Sci. 2012, 90, 980-987.
27. Lyons, T. J., Lipoprotein glycation and its metabolic consequences. Diabetes 1992, 41, 67-73.
28. Pieters, M., Covic, N., van der Westhuizen, F. H., Nagaswami, C. et al., Glycaemic control improves fibrin network characteristics in type 2 diabetes-a purified fibrinogen model. Thromb. Haemost. 2008, 99, 691-700.
29. Campenhout, A. V., Van Campenhout, C. M., Lagrou, A. R., Keenoy, B. M. Y., Transferrin modifications and lipid peroxidation: implications in diabetes mellitus. Free Radic. Res. 2003, 37, 1069-1077.
30. Mastorikou, M., Mackness, B., Liu, Y., Mackness, M., Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides. Diabet. Med. 2008, 25, 1049-1055.
31. Swamy-Mruthinti, S., Glycation decreases calmodulin binding to lens transmembrane protein, MIP. Biochim. Biophys. Acta 2001, 1536, 64-72.
32. Bloemendal, H., de Jong, W., Jaenicke, R., Lubsen, N. H. et al., Ageing and vision: structure, stability and function of lens crystallins. Prog. Biophys. Mol. Biol. 2004, 86, 407-485.
33. Qin, X. B., Goldfine, A., Krumrei, N., Grubissich, L. et al., Glycation inactivation of the complement regulatory protein CD59-A possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes 2004, 53, 2653-2661.
34. Langlois, M. R., Delanghe, J. R., Debuyzere, M. L., Lerouxroels, G. G., Glycation of human tissue and serum creatine-kinase. Clin. Chim. Acta 1992, 211, 83-92.
35. Beranek, M., Drsata, J., Palicka, V., Inhibitory effect of glycation on catalytic activity of alanine aminotransferase. Mol. Cell. Biochem. 2001, 218, 35-39.
36. Fitzgerald, C., Swearengin, T. A., Yeargans, G., McWhorter, D. et al., Non-enzymatic glycosylation (or glycation) and inhibition of the pig heart cytosolic aspartate aminotransferase by glyceraldehyde 3-phosphate. J. Enzyme Inhib. 1999, 15, 79-89.
37. Zhao, W., Devamanoharan, P. S., Varma, S. D., Fructose induced deactivation of antioxidant enzymes: preventive effect of pyruvate. Free Radic. Res. 2000, 33, 23-30.
38. Fujita, T., Suzuki, K., Tada, T., Yoshihara, Y. et al., Human erythrocyte bisphosphoglycerate mutase: Inactivation by glycation in vivo and in vitro. J. Biochem. 1998, 124, 1237-1244.
39. Murata, T., Miwa, I., Toyoda, Y., Okuda, J., Inhibition of glucose-induced insulin-secretion through inactivation of glucokinase by glyceraldehyde. Diabetes 1993, 42, 1003-1009.
40. Takahashi, M., Lu, Y. B., Myint, T., Fujii, J. et al., In-vivo glycation of aldehyde reductase, a major 3-deoxyglucosone reducing enzyme-identification of glycation sites. Biochemistry 1995, 34, 1433-1438.
41. Pietkiewicz, J., Gamian, A., Staniszewska, M., Danielewicz, R., Inhibition of human muscle-specific enolase by methylglyoxal and irreversible formation of advanced glycation end products. J. Enzyme Inhib. Med. Chem. 2009, 24, 356-364.
42. Yan, H., Harding, J. J., Glycation-induced inactivation and loss of antigenicity of catalase and superoxide dismutase. Biochem. J. 1997, 328, 599-605.
43. + occlusion. J. Biol. Chem. 1990, 265, 15058-15066.
44. Miyahara, Y., Ikeda, S., Muroya, T., Yasuoka, C. et al., N-epsilon-(carboxymethyl)lysine induces gamma-glutamylcysteine synthetase in RAW264.7 cells. Biochem. Biophys. Res. Commun. 2002, 296, 32-40.
45. Zahner, D., Liemans, V., Malaisselagae, F., Malaisse, W. J., Nonenzymatic glycation of phosphoglucoisomerase. Diabetes Res.Clin. Expl. 1989, 12, 165-168.
46. Neeper, M., Schmidt, A. M., Brett, J., Yan, S. D. et al., Cloning and expression of a cell-surface receptor for advanced glycosylation end-products of proteins. J. Biol. Chem. 1992, 267, 14998-15004.
47. Fritz, G., RAGE: a single receptor fits multiple ligands. Trends Biochem. Sci. 2011, 36, 625-632.
48. Ramasamy, R., Yan, S. F., Schmidt, A. M., The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul. Pharmacol. 2012, 57, 160-167.
49. Matsumoto, S., Yoshida, T., Murata, H., Harada, S. et al., Solution structure of the variable-type domain of the receptor for advanced glycation end products: new insight into AGE-RAGE interaction. Biochemistry 2008, 47, 12299-12311.
50. Kislinger, T., Fu, C. F., Huber, B., Qu, W. et al., N-epsilon-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 1999, 274, 31740-31749.
51. Daroux, M., Prevost, G., Maillard-Lefebvre, H., Gaxatte, C. et al., Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies. Diabetes Metab. 2010, 36, 1-10.
52. Wang, Z., Jiang, Y., Liu, N., Ren, L. et al., Advanced glycation end-product N-epsilon-carboxymethyl-lysine accelerates progression of atherosclerotic calcification in diabetes. Atherosclerosis 2012, 221, 387-396.
53. Cipollone, F., Iezzi, A., Fazia, M., Zucchelli, M. et al., The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques-role of glycemic control. Circulation 2003, 108, 1070-1077.
54. Hirose, A., Tanikawa, T., Mori, H., Okada, Y. et al., Advanced glycation end products increase endothelial permeability through the RAGE/Rho signaling pathway. FEBS Lett. 2010, 584, 61-66.
55. Tanji, N., Markowitz, G. S., Fu, C. F., Kislinger, T. et al., Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol. 2000, 11, 1656-1666.
56. Chuang, P. Y., Yu, Q., Fang, W., Uribarri, J. et al., Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int. 2007, 72, 965-976.
57. Pugliese, G., Pricci, F., Romeo, G., Pugliese, F. et al., Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 1997, 46, 1881-1887.
58. Brizzi, M. F., Dentelli, P., Rosso, A., Calvi, C. et al., RAGE- and TGF-beta receptor-mediated signals converge on STAT5 and P21(waf) to control cell-cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy. FASEB J. 2004, 18, 1249-1251.
59. Watson, A. M. D., Gray, S. P., Jiaze, L., Soro-Paavonen, A. et al., Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. Diabetes 2012, 61, 2105-2113.
60. Hu, P. F., Lai, D. W., Lu, P. L., Gao, J. et al., ERK and Akt signaling pathways are involved in advanced glycation end product-induced autophagy in rat vascular smooth muscle cells. Int. J. Mol. Med. 2012, 29, 613-618.
61. Boulanger, E., Wautier, M. P., Wautier, J. L., Boval, B. et al., AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int. 2002, 61, 148-156.
62. Kang, R., Tang, D. L., Lotze, M. T., Zeh, H. J., RAGE regulates autophagy and apoptosis following oxidative injury. Autophagy 2011, 7, 442-444.
63. Brune, M., Muller, M., Melino, G., Bierhaus, A. et al., Depletion of the receptor for advanced glycation end products (RAGE) sensitizes towards apoptosis via p53 and p73 posttranslational regulation. Oncogene 2012, DOI: 10.1038/onc.2012.150.
64. He, M., Kubo, H., Morimoto, K., Fujino, N. et al., Receptor for advanced glycation end products binds to phosphatidylserine and assists in the clearance of apoptotic cells. EMBO Rep. 2011, 12, 358-364.
65. Zhu, Y. X., Shu, T. T., Lin, Y., Wang, H. D. et al., Inhibition of the receptor for advanced glycation endproducts (RAGE) protects pancreatic beta-cells. Biochem. Biophys. Res. Commun. 2011, 404, 159-165.
66. Yan, S. D., Chen, X., Fu, J., Chen, M. et al., RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996, 382, 685-691.
67. Arancio, O., Zhang, H. P., Chen, X., Lin, C. et al., RAGE potentiates a beta-induced perturbation of neuronal function in transgenic mice. EMBO J. 2004, 23, 4096-4105.
68. Byun, K., Bayarsaikhan, E., Kim, D., Son, M. et al., Activated microglial cells synthesize and secrete AGE-albumin. Anat. Cell Biol. 2012, 45, 47-52.
69. Guglielmotto, M., Aragno, M., Tamagno, E., Vercellinatto, I. et al., AGEs/RAGE complex upregulates BACE1 via NF-kappa B pathway activation. Neurobiol. Aging 2012, 33, 196.e 13-196.e 27.
70. Deane, R., Yan, S. D., Submamaryan, R. K., LaRue, B. et al., RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 2003, 9, 907-913.
71. Huttunen, H. J., Fages, C., Rauvala, H., Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappa B require the cytoplasmic domain of the receptor but different downstream signaling pathways. J. Biol. Chem. 1999, 274, 19919-19924.
72. Li, X. H., Lv, B. L., Xie, J. Z., Liu, J. et al., AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiol. Aging 2012, 33, 1400-1410.
73. Yin, Q. Q., Dong, C. F., Dong, S. Q., Dong, X. L. et al., AGEs induce cell death via oxidative and endoplasmic reticulum stresses in both human SH-SY5Y neuroblastoma cells and rat cortical neurons. Cell. Mol. Neurobiol. 2012, 32, 1299-1309.
74. Bhawal, U. K., Ozaki, Y., Nishimura, M., Sugiyama, M. et al., Association of expression of receptor for advanced glycation end products and invasive activity of oral squamous cell carcinoma. Oncology 2005, 69, 246-255.
75. Kang, R., Tang, D., Schapiro, N. E., Livesey, K. M. et al., The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ. 2010, 17, 666-676.
76. Shang, L. S., Ananthakrishnan, R., Li, Q., Quadri, N. et al., RAGE modulates hypoxia/reoxygenation injury in adult murine cardiomyocytes via JNK and GSK-3 beta signaling pathways. Plos One 2010, 5, e10092.
77. Macaione, V., Aguennouz, M., Rodolico, C., Mazzeo, A. et al., RAGE-NF-kappa B pathway activation in response to oxidative stress in facioscapulohumeral muscular dystrophy. Acta. Neurol. Scand. 2007, 115, 115-121.
78. Gong, F. Q., Zhang, Y., Xie, C. H., Zhu, W. H. et al., Expression of receptor for advanced glycation end products (RAGE) on the surface of circulating endothelial cells is upregulated in Kawasaki disease. Pediatr. Res. 2012, 71, 720-724.
79. Taguchi, A., Blood, D. C., del Toro, G., Canet, A. et al., Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405, 354-360.
80. Kikuchi, S., Shinpo, K., Takeuchi, M., Yamagishi, S. et al., Glycation-a sweet tempter for neuronal death. Brain Res. Rev. 2003, 41, 306-323.
81. Miranda, H. V., Outeiro, T. F., The sour side of neurodegenerative disorders: the effects of protein glycation. J. Pathol. 2010, 221, 13-25.
82. Snow, L. M., Fugere, N. A., Thompson, L. V., Advanced glycation end-product accumulation and associated protein modification in type II skeletal muscle with aging. J. Gerontol. A. Biol. Sci. Med. Sci. 2007, 62, 1204-1210.
83. Ledesma, M. D., Bonay, P., Colaco, C., Avila, J., Analysis of microtubule-associated protein tau glycation in paired helical filaments. J. Biol. Chem. 1994, 269, 21614-21619.
84. Chen, K., Maley, J., Yu, P. H., Potential inplications of endogenous aldehydes in beta-amyloid misfolding, oligomerization and fibrillogenesis. J. Neurochem. 2006, 99, 1413-1424.
85. Lee, D., Park, C. W., Paik, S. R., Choi, K. Y., The modification of alpha-synuclein by dicarbonyl compounds inhibits its fibril-forming process. Biochim. Biophys. Acta 2009, 1794, 421-430.
86. Kumar, P. A., Kumar, M. S., Reddy, G. B., Effect of glycation on alpha-crystallin structure and chaperone-like function. Biochem. J. 2007, 408, 251-258.
87. Austin, G. E., Mullins, R. H., Morin, L. G., Non-enzymatic glycation of individual plasma-proteins in normoglycemic and hyperglycemic patients. Clin. Chem. 1987, 33, 2220-2224.
88. Zhang, Q. B., Monroe, M. E., Schepmoes, A. A., Clauss, T. R. W. et al., Comprehensive identification of glycated peptides and their glycation motifs in plasma and erythrocytes of control and diabetic subjects. J. Proteome. Res. 2011, 10, 3076-3088.
89. Cohen, M. P., Clements, R. S., Measuring glycated proteins: clinical and methodological aspects. Diabetes Technol. Ther. 1999, 1, 57-70.
90. Koga, M., Kasayama, S., Clinical impact of glycated albumin as another glycemic control marker. Endocr. J. 2010, 57, 751-762.
91. Rosca, M. G., Mustata, T. G., Kinter, M. T., Ozdemir, A. M. et al., Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am. J. Physiol. Renal. Physiol. 2005, 289, F420-F430.
92. Chougale, A. D., Bhat, S. P., Bhujbal, S. V., Zambare, M. R. et al., Proteomic analysis of glycated proteins from streptozotocin-induced diabetic rat kidney. Mol. Biotechnol. 2012, 50, 28-38.
93. Madian, A. G., Myracle, A. D., Diaz-Maldonado, N., Rochelle, N. S. et al., Differential carbonylation of proteins as a function of in vivo oxidative stress. J. Proteome. Res. 2011, 10, 3959-3972.
94. Barati, M. T., Merchant, M. L., Kain, A. B., Jevans, A. W. et al., Proteomic analysis defines altered cellular redox pathways and advanced glycation end-product metabolism in glomeruli of db/db diabetic mice. Am. J. Physiol. Renal. Physiol. 2007, 293, F1157-F1165.
95. Mandelkow, E. M., Mandelkow, E., Tau in Alzheimer's disease. Trends Cell. Biol. 1998, 8, 425-427.
96. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q. et al., Alpha-synuclein in Lewy bodies. Nature 1997, 388, 839-840.
97. Ramirez-Boo, M., Priego-Capote, F., Hainard, A., Gluck, F. et al., Characterization of the glycated human cerebrospinal fluid proteome. J. Proteomics, 2012, 75, 4766-4782.
98. Grossman, H., Bergmann, C., Parker, S., Dementia: a brief review. Mt. Sinai. J. Med. 2006, 73, 985-992.
99. Haan, M. N., Therapy insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat. Clin. Pract. Neurol. 2006, 2, 159-166.
100. Luth, H. J., Ogunlade, V., Kuhla, B., Kientsch-Engel, R. et al., Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains. Cereb. Cortex. 2005, 15, 211-220.
101. Sato, T., Shimogaito, N., Wu, X., Kikuchi, S. et al., Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen. 2006, 21, 197-208.
102. Vitek, M. P., Bhattacharya, K., Glendening, J. M., Stopa, E. et al., Advanced glycation end-products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. USA 1994, 91, 4766-4770.
103. Smith, M. A., Taneda, S., Richey, P. L., Miyata, S. et al., Advanced Maillard reaction end-products are associated with Alzheimer-disease pathology. Proc. Natl. Acad. Sci. USA 1994, 91, 5710-5714.
104. Necula, M., Kuret, J., Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro. J. Biol. Chem. 2004, 279, 49694-49703.
105. Reynolds, C. H., Betts, J. C., Blackstock, W. P., Nebreda, A. R. et al., Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3 beta. J. Neurochem. 2000, 74, 1587-1595.
106. Li, G. Y., Chang, M., Jiang, H. Y., Xie, H. R. et al., Proteomics analysis of methylglyoxal-induced neurotoxic effects in SH-SY5Y cells. Cell Biochem. Funct. 2011, 29, 30-35.
107. Yan, S. D., Yan, S. F., Chen, X., Fu, J. et al., Nonenzymatically glycated-Tau in Alzheimers disease induces neuronal oxidant stress resulting in cytokine gene-expression and release of amyloid beta-peptide. Nat. Med. 1995, 1, 693-699.
108. Chen, L., Wei, Y., Wang, X. Q., He, R. Q., Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products. PLoS One 2010, 5, e9052.
109. Padmaraju, V., Bhaskar, J. J., Rao, U. J., Salimath, P. V. et al., Role of advanced glycation on aggregation and DNA binding properties of alpha-synuclein. Mol. Neurobiol. 2011, 24, 211-221.
110. Guerrero, E., Vasudevaraju, P., Hegde, M. L., Britton, G. B. et al., Recent advances in alpha-synuclein functions, advanced glycation, and toxicity: implications for Parkinson's disease. Mol. Neurobiol. 2012, in press.
111. Shaikh, S., Nicholson, L. F., Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation. J. Neurosci. Res. 2008, 86, 2071-2082.
112. Dalfo, E., Portero-Otin, M., Ayala, V., Martinez, A. et al., Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J. Neuropath. Exp. Neurol. 2005, 64, 816-830.
113. Choonara, Y. E., Pillay, V., du Toit, L. C., Modi, G. et al., Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders. Int. J. Mol. Sci. 2009, 10, 2510-2557.
114. Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A. et al., Mutations in Cu/Zn superoxide-dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362, 59-62.
115. Shibata, N., Hirano, A., Kato, S., Nagai, R. et al., Advanced glycation endproducts are deposited in neuronal hyaline inclusions: a study on familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Acta Neuropathol. 1999, 97, 240-246.
116. Kaufmann, E., Boehm, B. O., Sussmuth, S. D., Kientsch-Engel, R. et al., The advanced glycation end-product N-epsilon-(carboxymethyl)lysine level is elevated in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurosci. Lett. 2004, 371, 226-229.
117. Chou, S. M., Wang, H. S., Taniguchi, A., Bucala, R., Advanced glycation end products in neurofilament conglomeration of motoneurons in familial and sporadic amyotrophic lateral sclerosis. Mol. Med. 1998, 4, 324-332.
118. Westermark, P., Sletten, K., Johansson, B., Cornwell, G. G., Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc. Natl. Acad. Sci. USA 1990, 87, 2843-2845.
119. Sousa, M. M., Du Yan, S., Stern, D., Saraiva, M. J., Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Lab. Invest. 2000, 80, 1101-1110.
120. Sousa, M. M., Du Yan, S., Fernandes, R., Guimaraes, A. et al., Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J. Neurosci. 2001, 21, 7576-7586.
121. Knight, R. S., Will, R. G., Prion diseases. J. Neurol. Neurosurq. Psychiatry 2004, 75, i36-i42.
122. Saborio, G. P., Permanne, B., Soto, C., Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 2001, 411, 810-813.
123. Choi, Y. G., Kim, J. I., Jeon, Y. C., Park, S. J. et al., Nonenzymatic glycation at the N terminus of pathogenic prion protein in transmissible spongiform encephalopathies. J. Biol. Chem. 2004, 279, 30402-30409.
124. Lee, A. T., Cerami, A., Role of glycation in aging. Ann. NY Acad. Sci. 1992, 663, 63-70.
125. Brownlee, M., Advanced protein glycosylation in diabetes and aging. Ann. Rev. Med. 1995, 46, 223-234.
126. Ahmed, M. U., Frye, E. B., Degenhardt, T. P., Thorpe, S. R. et al., N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem. J. 1997, 324, 565-570.
127. Kimura, T., Takamatsu, J., Ikeda, K., Kondo, A. et al., Accumulation of advanced glycation end products of the Maillard reaction with age in human hippocampal neurons. Neurosci. Lett. 1996, 208, 53-56.
128. vanBoekel, M. A. M., Hoogakker, S. E., Harding, J. J., deJong, W. W., The influence of some post-translational modifications on the chaperone-like activity of alpha-crystallin. Ophthalmic Res. 1996, 28, 32-38.
129. Garlick, R. L., Mazer, J. S., Chylack, L. T., Tung, W. H. et al., Nonenzymatic glycation of human lens crystallin-effect of aging and diabetes mellitus. J. Clin. Invest. 1984, 74, 1742-1749.
130. CervantesLaurean, D., Jacobson, E. L., Jacobson, M. K., Glycation and glycoxidation of histones by ADP-ribose. J. Biol. Chem. 1996, 271, 10461-10469.
131. Guedes, S., Vitorino, R., Domingues, M. R., Amado, F. et al., Glycation and oxidation of histones H2B and H1: in vitro study and characterization by mass spectrometry. Anal. Bioanal. Chem. 2011, 399, 3529-3539.
132. Konova, E., Baydanoff, S., Atanasova, M., Velkova, A., Age-related changes in the glycation of human aortic elastin. Exp. Gerontol. 2004, 39, 249-254.
133. Atanasova, M., Konova, E., Betova, T., Baydanoff, S., Non-enzymatic glycation of human fibrillin-1. Gerontology 2009, 55, 73-81.
134. Paul, R. G., Bailey, A. J., Glycation of collagen: the basis of its central role in the late complications of ageing and diabetes. Int. J. Biochem. Cell Biol. 1996, 28, 1297-1310.
135. Park, K. H., Shin, D. G., Kim, J. R., Cho, K. H., Senescence-related truncation and multimerization of apolipoprotein A-I in high-density lipoprotein with an elevated level of advanced glycated end products and cholesteryl ester transfer activity. J. Gerontol. A Biol. Sci. Med. Sci. 2010, 65, 600-610.
136. Dai, Z. Y., Wang, B. L., Sun, G., Fan, X. J. et al., Identification of glucose-derived cross-linking sites in ribonuclease A. J. Proteome Res. 2008, 7, 2756-2768.
137. Freire, A. P., Ferreira, A., Gomes, R., Cordeiro, C., Anti-glycation defences in yeast. Biochem. Soc. Trans. 2003, 31, 1409-1412.
138. Piper, P. W., Long-lived yeast as a model for ageing research. Yeast 2006, 23, 215-226.
139. Gomes, R. A., Miranda, H. V., Silva, M. S., Graca, G. et al., Yeast protein glycation in vivo by methylglyoxal-molecular modification of glycolytic enzymes and heat shock proteins. FEBS J. 2006, 273, 5273-5287.
140. Molin, M., Pilon, M., Blomberg, A., Dihydroxyacetone-induced death is accompanied by advanced glycation endproduct formation in selected proteins of Saccharomyces cerevisiae and Caenorhabditis elegans. Proteomics 2007, 7, 3764-3774.
141. Semchyshyn, H. M., Lozinska, L. M., Miedzobrodzki, J., Lushchak, V. I., Fructose and glucose differentially affect aging and carbonyl/oxidative stress parameters in Saccharomyces cerevisiae cells. Carbohydr. Res. 2011, 346, 933-938.
142. Hamelin, M., Mary, J., Vostry, M., Friguet, B. et al., Glycation damage targets glutamate dehydrogenase in the rat liver mitochondrial matrix during aging. FEBS J. 2007, 274, 5949-5961.
143. Cai, W. J., He, J. C., Zhu, L., Chen, X. et al., Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet-association with increased AGER1 expression. Am. J. Pathol. 2007, 170, 1893-1902.
144. Bachmeier, B. E., Nerlich, A. G., Rohrbach, H., Schleicher, E. D. et al., Maillard products as biomarkers in cancer. Ann. NY Acad. Sci. 2008, 1126, 283-287.
145. Abe, R., Shimizu, T., Sugawara, H., Watanabe, H. et al., Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J. Invest. Dermatol. 2004, 122, 461-467.
146. Korwar, A. M., Bhonsle, H. S., Chougale, A. D., Kote, S. S. et al., Analysis of AGE modified proteins and RAGE expression in HER2/neu negative invasive ductal carcinoma. Biochem. Biophys. Res. Commun. 2012, 419, 490-494.
147. Rao, G. N., Cotlier, E., Aspirin prevents the nonenzymatic glycosylation and carbamylation of the human eye lens crystallins in vitro. Biochem. Biophys. Res. Commun. 1988, 151, 991-996.
148. Sulochana, K. N., Punitham, R., Ramakrishnan, S., Beneficial effect of lysine and amino acids on cataractogenesis in experimental diabetes through possible antiglycation of lens proteins. Exp. Eye Res. 1998, 67, 597-601.
149. Mendez, J. D., Leal, L. I., Inhibition of in vitro pyrraline formation by l-arginine and polyamines. Biomed. Pharm. 2004, 58, 598-604.
150. Hipkiss, A. R., Michaelis, J., Syrris, P., Kumar, S. et al., Carnosine protects proteins against in vitro glycation and cross-linking. Biochem. Soc. Trans. 1994, 22, 399S.
151. Golegaonkar, S. B., Bhonsle, H. S., Boppana, R., Kulkarni, M. J., Discovery of rifampicin as a new anti-glycating compound by matrix-assisted laser desorption/ionization mass spectrometry-based insulin glycation assay. Eur. J. Mass Spectrom. (Chichester, Eng) 2010, 16, 221-226.
152. Guiotto, A., Ruzza, P., Babizhayev, M. A., Calderan, A., Malondialdehyde scavenging and aldose-derived Schiff bases' transglycation properties of synthetic histidyl-hydrazide carnosine analogs. Bioorg. Med. Chem. 2007, 15, 6158-6163.
153. Brownlee, M., Vlassara, H., Kooney, A., Ulrich, P. et al., Aminoguanidine prevents diabetes-induced arterial-wall protein cross-linking. Science 1986, 232, 1629-1632.
154. Thornalley, P. J., Yurek-George, A., Argirov, O. K., Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem. Pharmacol. 2000, 60, 55-65.
155. Thornalley, P. J., Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch. Biochem. Biophys. 2003, 419, 31-40.
156. Ruggiero-Lopez, D., Lecomte, M., Moinet, G., Patereau, G. et al., Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem. Pharmacol. 1999, 58, 1765-1773.
157. Nakamura, S., Makita, Z., Ishikawa, S., Yasumura, K. et al., Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997, 46, 895-899.
158. Miyata, T., Ishikawa, S., Asahi, K., Inagi, R. et al., 2-Isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage. FEBS Lett. 1999, 445, 202-206.
159. Khalifah, R. G., Baynes, J. W., Hudson, B. G., Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem. Biophys. Res. Commum. 1999, 257, 251-258.
160. Voziyan, P. A., Hudson, B. G., Pyridoxamine: the many virtues of a Maillard reaction inhibitor. Ann. NY Acad. Sci. 2005, 1043, 807-816.
161. Nagai, R., Murray, D. B., Metz, T. O., Baynes, J. W., Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes 2012, 61, 549-559.
162. Rahbar, S., Figarola, J. L., Novel inhibitors of advanced glycation endproducts. Arch. Biochem. Biophys. 2003, 419, 63-79.
163. Stracke, H., Hammes, H. P., Werkmann, D., Mavrakis, K. et al., Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp. Clin. Endocrinol. Diabetes 2001, 109, 330-336.
164. Babaei-Jadidi, R., Karachalias, N., Ahmed, N., Battah, S. et al., Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003, 52, 2110-2120.
165. Hammes, H. P., Du, X. L., Edelstein, D., Taguchi, T. et al., Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med. 2003, 9, 294-299.
166. Vasan, S., Foiles, P., Founds, H., Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch. Biochem. Biophys. 2003, 419, 89-96.
167. Saraswat, M., Reddy, P. Y., Muthenna, P., Reddy, G. B., Prevention of non-enzymic glycation of proteins by dietary agents: prospects for alleviating diabetic complications. Br. J. Nutr. 2009, 101, 1714-1721.
168. Miyata, T., de Strihou, C. V., Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation. Arch. Biochem. Biophys. 2003, 419, 50-54.
169. Park, L., Raman, K. G., Lee, K. J., Lu, Y. et al., Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 1998, 4, 1025-1031.
170. Barile, G. R., Pachydaki, S. I., Tari, S. R., Lee, S. E. et al., The RAGE axis in early diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2005, 46, 2916-2924.
171. Flyvbjerg, A., Denner, L., Schrijvers, B. F., Tilton, R. G. et al., Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 2004, 53, 166-172.
172. De Vriese, A. S., Flyvbjerg, A., Mortier, S., Tilton, R. G. et al., Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J. Am. Soc. Nephrol. 2003, 14, 2109-2118.
173. Muller-Krebs, S., Kihm, L. P., Madhusudhan, T., Isermann, B. et al., Human RAGE antibody protects against AGE-mediated podocyte dysfunction. Nephrol. Dial. Transplant 2012, 27, 3129-3136.
174. Yamagishi, S. I., Nakamura, K., Matsui, T., Noda, Y. et al., Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr. Pharm. Des. 2008, 14, 487-495.
175. Yamagishi, S. I., Nakamura, K., Matsui, T., Ueda, S. et al., Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin. Investiq. Drug 2008, 17, 983-996.
176. Han, Y. T., Choi, G. I., Son, D., Kim, N. J. et al., Ligand-based design, synthesis, and biological evaluation of 2-aminopyrimidines, a novel series of receptor for advanced glycation end products (RAGE) inhibitors. J. Med. Chem. 2012, 55, 9120-9135.
177. Wu, X. L., Monnier, V. M., Enzymatic deglycation of proteins. Arch. Biochem. Biophys. 2003, 419, 16-24.
178. Szwergold, B. S., Intrinsic toxicity of glucose, due to non-enzymatic glycation, is controlled in-vivo by deglycation systems including: FN3K-mediated deglycation of fructosamines and transglycation of aldosamines. Med. Hypotheses 2005, 65, 337-348.
179. Szwergold, B. S., Howell, S. K., Beisswenger, P. J., Transglycation-a potential new mechanism for deglycation of Schiff's bases. Ann. NY Acad. Sci. 2005, 1043, 845-864.
180. Takahashi, M., Fujii, J., Teshima, T., Suzuki, K. et al., Identity of a major 3-deoxyglucosone-reducing enzyme with aldehyde reductase in rat-liver established by amino-acid sequencing and cDNA expression. Gene 1993, 127, 249-253.
181. Zhang, L., Bukulin, M., Kojro, E., Roth, A. et al., Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J. Biol. Chem. 2008, 283, 35507-35516.
182. Galichet, A., Weibel, M., Heimann, C. W., Calcium-regulated intramembrane proteolysis of the RAGE receptor. Biochem. Biophys. Res. Commum. 2008, 370, 1-5.
183. Ojima, A., Matsui, T., Maeda, S., Takeuchi, M. et al., Glucose-dependent insulinotropic polypeptide (GIP) inhibits signaling pathways of advanced glycation end products (AGEs) in endothelial cells via its antioxidative properties. Horm. Metab. Res. 2012, 44, 501-505.